Thrivent Financial for Lutherans Has $38.51 Million Stock Holdings in Stryker Corporation $SYK

Thrivent Financial for Lutherans increased its position in Stryker Corporation (NYSE:SYK) by 12.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 97,365 shares of the medical technology company’s stock after purchasing an additional 10,975 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Stryker were worth $38,507,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Cresset Asset Management LLC lifted its stake in shares of Stryker by 20.1% in the 1st quarter. Cresset Asset Management LLC now owns 21,313 shares of the medical technology company’s stock valued at $7,952,000 after purchasing an additional 3,568 shares during the period. Steward Partners Investment Advisory LLC boosted its position in shares of Stryker by 17.1% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 26,599 shares of the medical technology company’s stock worth $9,902,000 after purchasing an additional 3,883 shares during the last quarter. Brooklyn Investment Group grew its stake in shares of Stryker by 8.5% during the first quarter. Brooklyn Investment Group now owns 3,092 shares of the medical technology company’s stock worth $1,151,000 after purchasing an additional 243 shares during the period. Finally, Aptus Capital Advisors LLC increased its holdings in Stryker by 8.9% in the first quarter. Aptus Capital Advisors LLC now owns 100,987 shares of the medical technology company’s stock valued at $37,592,000 after purchasing an additional 8,272 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SYK. Citigroup reduced their target price on Stryker from $455.00 to $420.00 and set a “buy” rating on the stock in a report on Thursday. Truist Financial boosted their price objective on shares of Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a report on Friday, November 14th. Wells Fargo & Company increased their target price on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Redburn Partners set a $420.00 price target on shares of Stryker in a research report on Thursday, September 18th. Finally, Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Twelve research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $431.83.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the transaction, the chief financial officer directly owned 6,694 shares in the company, valued at $2,449,200.72. This trade represents a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 522,118 shares of company stock worth $185,381,932 in the last three months. Insiders own 5.20% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $355.34 on Tuesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. The firm has a market cap of $135.89 billion, a price-to-earnings ratio of 46.69, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. The stock’s 50-day moving average is $366.60 and its 200-day moving average is $378.26. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. The firm had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be given a dividend of $0.88 per share. This is a boost from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s payout ratio is presently 44.15%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.